Biopharmaceutical companies are facing major challenges today, including rising drug manufacturing costs and lower production volumes related to unpredictable demands. To achieve the necessary reductions in both costs of goods (CoG) and infrastructure and operational costs, biopharmaceutical manufacturers integrate process intensification strategies into their production schemes. Novasep has embedded specific features into its BioSC™ platform to enable and accelerate process intensification (two key examples being viral inactivation steps management and in-line buffer preparation). BioSC Predict, Exclusive Simulation and Optimization Software:…